Diabetes mellitus and cardiovascular diseases are challenging medical and social problems. Patients with diabetes mellitus are at a higher risk of developing vascular dysfunction and hypertension. Cumulative evidence suggests that oxidative stress may play a key role in the development of diseases. It has been found that oxidative stress is associated with several cardiovascular diseases, including atherosclerosis, hypertension, heart failure, stroke, and diabetes, and plays a fundamental role in endothelial dysfunction associated with these diseases -. Further, oxidative stress plays a major role in the pathogenesis of both types of diabetes mellitus. 

High levels of free radicals and the decline of antioxidant defense mechanisms lead to damage of cellular organelles and enzymes, increased lipid peroxidation, and development of insulin resistance . The vascular and systemic complications in diabetes are associated with hyperglycemia-induced overproduction of reactive oxygen species ,

Other studies showed that overproduction of reactive oxygen and nitrogen species, lowered antioxidant defense and alterations of enzymatic pathways in humans with poorly controlled diabetes mellitus can contribute to endothelial, vascular and neurovascular dysfunction . Insulin resistance is associated with reduced intracellular antioxidant defense, and therefore diabetic patients may have a defective intracellular antioxidant response that causes diabetic complications -.

The combination of the low levels of antioxidants and raised levels of free radical play a major role in delaying wound healing . It has been found that chronic leg ulcers contain localized oxidative stress . The recent finding revealed that insulin resistance is associated in humans with reduced intracellular antioxidant . Interestingly, antioxidants improve insulin sensitivity and help in wound healing ,.

Along with others, the investigators used microcurrent for treatment of chronic wounds and ulcers -. In an earlier work, The Electro Pressure Regeneration Therapy (EPRT) device which produces a current range of 3 mA down to 100 nA, was used for treatment of chronic wounds and ulcers associated with chronic disease .  Similar studies using the eBalance device (CellMedX, Vancouver, BC) were shown to be efficacious in the treatment of diabetes, hypertension and chronic wounds [70].

Both the EPRT and eBalance devices have been used to deliver electrons to tissues and then saturated free radicals with required electrons. The actual tissue regeneration, along with concomitant improvement noted in the general condition of the patient, points to a highly potent antioxidant effect on local tissues, as well as on tissues in general. This reduces free radicals and might facilitate tissue repair. This device is used as a model to deliver electrons to the body, including mitochondria and presumably working as an antioxidant device. It was thought reasonable to use on patients with diabetes mellitus, hypertension and chronic wounds, to test whether delivering electrons to the body might help eliminate underlying oxidative stress, stabilize mitochondria and prevent further formation of excess free radicals.

Oxidative stress plays a major role in the pathogenesis of both types of diabetes mellitus and cardiovascular diseases including hypertension. The low levels of antioxidants accompanied by raised levels of markers of free radical damage play a major role in delaying wound healing. Ultra-low microcurrent presumably has an antioxidant effect, and it was shown to accelerate wound healing. 

The purpose of these studies was to investigate the efficacy of ultra-low microcurrent delivered by the Electro Pressure Regeneration Therapy (EPRT) device (EPRT Technologies-USA, Simi Valley, CA) and eBalance device (CellMedX, Vancouver, BC) in the management of diabetes, hypertension and chronic wounds[70]. The EPRT and eBalance are electrical devices that send a pulsating stream of electrons in a relatively low concentration to targeted areas or throughout the body. 

These devices are noninvasive and delivers electrical currents that mimic the endogenous electric energy of the human body. It is a rechargeable battery-operated device that delivers a direct current (maximum of 3 milliAmperes) of one polarity for 11.5 minutes, which then switched to the opposite polarity for another 11.5 minutes. The resulting cycle time is approximately 23 min or 0.000732 Hz and delivers a square wave bipolar current with a voltage ranging from 5V up to a maximum of 40 V. The device produces a current range of 3 mA down to 100 nA. Twelve patients with long standing diabetes, hypertension and unhealed wounds were treated with EPRT. 

The patients were treated approximately for 3.5 h/day/5 days a week. Assessment of ulcer was based on scale used by National Pressure Ulcer Advisory Panel Consensus Development Conference. Similar case studies have been conducted with use of the eBalance in patients with hypertension, diabetes and wounds resulting from the latter. ultra-low microcurrents were found to be a safe and effective therapy for this patient population. 

Patients were followed-up with daily measurement of blood pressure and blood glucose level, and their requirement for medications was recorded. Treatment continued from 2-4 months according to their response. Results showed that diabetes mellitus and hypertension were well controlled after using this device, and their wounds were markedly healed (30-100%). The patients either reduced their medication or completely stopped after the course of treatment. No side effects were reported. This supports the safety of ultra-low microcurrent in the treatment of patients with diabetes and cardiovascular disease. 

Electro Pressure Regeneration Therapy Device

The EPRT device is an electrical device that sends a pulsating stream of electrons in a relatively low concentration throughout the body. The device is noninvasive and delivers electrical currents that mimic the endogenous electric energy of the human body. It is a rechargeable battery-operated device that delivers a direct current (maximum of 3 milliAmperes) of one polarity for 11.5 minutes, which then switched to the opposite polarity for another 11.5 minutes. 

In several of the studies, the ultra-low microccurent device was designed to switch the direction of current flow halfway through the cycle. The resulting cycle time is approximately 23min or 0.000732 Hz and delivers a square wave bipolar current with a voltage ranging from 5V up to a maximum of 40 V. The device produces a current range of 3 mA down to 100 nA. Electrodes are applied in 2 layers, and tap water is used as the conducting medium. The wraps cover a large surface area, thus reducing resistance and allowing an optimum number of electrons to flow freely into tissues.

The results of this preliminary trial showed that ultra-low microcurrent has apparent therapeutic effects on diabetes, hypertension and wound healing. Presumably, one of mechanisms of action is its antioxidant activity. The action of EPRT is to produce electrical pressure rather than an electrical jolt as produced by a Transcutaneous Electrical Nerve Stimulator. Whereas Transcutaneous Electrical Nerve Stimulator device can produce a current varying from 1uA to 100 mA, the EPRT ranges from 100 nA to 3 mA. Moreover, Transcutaneous Electrical Nerve Stimulator frequency range is from 0.5 to 40,000 Hz with a range of cycle times from 2 seconds to 0.025 milliseconds. The EPRT has a frequency of approximately 0.000732Hz which gives a frequency time of 22.77 minutes. Namely, Transcutaneous Electrical Nerve Stimulator with power of 10 mA and a frequency of 1 Hz is delivering approximately 6x10 (14) electrons per cycle. As the cycle is 1 second all these electrons were delivered in that period as a jolt. 

The EPRT at a setting of 100 nA is delivering 8.129x10 (14) per cycle. But as this amount is being delivered over a 23 minute period (at rate of 6x10 (11) electrons per second) this behaves as a pressure instead of a jolt. This steady stream of electrons is what makes the EPRT a super antioxidant and not only does this correct malalignments in the cells electrical system but it also eliminates free radicals and then stimulates the mitochondria to produce ATP.

Microcurrent has been successfully used to enhance soft tissue healing and to treat fracture nonunion ,. Microcurrent relieves myocontracture and can enhance conventional rehabilitation programs for children with cerebral palsy . Studies suggest that microcurrent therapy is effective at relieving the side effects of radiation therapy . The investigators have found that direct electrical therapy was effective in healing gum abscess and accelerated wound healing . These areas of research provide new applications for the use of microcurrents to enhance the lives of those living with both disease and the complications of treatment.

Substances that increase electrical field, such as prostaglandin E2, enhance the wound healing rate and increase cell division -. Electrical fields stimulate secretion of growth factor . Low mA current stimulates adenosine triphosphate production . It is discovered in another study that microcurrent stimulates dermal fibroblasts and U937 cells to secrete transforming growth factor-β1, a major regulator of cell-mediated inflammation and tissue regeneration .

Insulin resistance plays a major role in the development of several metabolic abnormalities and diseases such as type 2 diabetes mellitus, obesity and the metabolic syndrome . In these conditions there is an elevation of both glucose and free fatty acid levels in the blood and an increase in oxidative stress ,. The high degree of oxidative stress might have an important role in decreasing insulin responsiveness -.

Many studies have suggested that ß-cell dysfunction results from prolonged exposure to high glucose and elevated free fatty levels . High glucose concentrations induce mitochondrial reactive oxygen species, which suppresses the first phase of glucose-induced insulin secretion . ß-cells are particularly sensitive to reactive oxygen species because they are low in antioxidant enzymes such as catalase, glutathione peroxidase, and superoxide dismutase . Therefore, the oxidative stress might damage mitochondria and markedly blunt insulin secretion 

Recent studies suggested that ß-cell lipotoxicity is enhanced by concurrent hyperglycemia and that oxidative stress may be the mediator ,. An increase in insulin, free fatty acid, and/or glucose levels can increase reactive oxygen species production and oxidative stress, as well as activate stress-sensitive pathways . Many studies show that postprandial hyperglycemia is associated with oxidative stress generation . Repeated exposure to hyperglycemia and increased levels of free fatty acid can lead to ß-cell dysfunction that may become irreversible over time. It has been suggested that oxidative stress might be the mediator of damage to cellular components of insulin production ,.

A major source of cellular reactive oxygen species is mitochondria, whose dysfunction contributes to pathological conditions such as vascular complications of diabetes, neurodegenerative diseases and cellular senescence -. Source of reactive oxygen species in insulin secreting pancreatic β-cells and cells that are targets for insulin action is considered to be the mitochondrial electron transport chain. 

Hyperglycemia and lipotoxicity in obesity and related disorders are associated with mitochondrial dysfunction and oxidative stress ,. Oxidative stress-induced activation of NF-κB signaling might be associated with the pathogenesis of insulin resistance and type 2 diabetes -. In obesity and type 2 diabetes it has been reported that antioxidants and IKK-B inhibitors protect against insulin resistance ,.

Data show that increased lipid peroxidation in NIDDM has implications for vascular disease in diabetes . Oxidative stress plays an important role in the pathogenesis of cardiovascular diseases including hypertension . Clinical studies suggest the occurrence of increased reactive oxygen species production in humans with essential hypertension ,. Oxidative stress is considered to be a unifying mechanism for hypertension and atherosclerosis ,.

Oxygen free radicals play a major role in the failure of ischemic wound healing, while antioxidants partly improve the healing in ischemic skin wounds . Oxygen free radicals mediate the inhibition of wound healing following ischemia-reperfusion and sepsis . It seems that diabetes mellitus, cardiovascular disease, such as hypertension, and delayed wound healing have a common important basic pathogenesis, which is related to imbalance between free radical production and removal. 

The use of ultra-low microcurrent might help in stabilizing mitochondria, working as antioxidants and therefore, enhancing normal function of β-cells and vascular tissue. Several clinical trials have demonstrated that treatment with vitamin E, vitamin C, or glutathione improves insulin sensitivity in insulin-resistant individuals ,. The acute effects of hyperglycemia-dependent endothelial cells dysfunction are counterbalanced by antioxidants -. But clinical trials with antioxidants, in particular with vitamin E, have failed to show any beneficial effect . However, antioxidant therapy with vitamin E or other antioxidants is limited to sourcing already formed oxidants and may be considered symptomatic instead of a causal treatment for oxidative stress . Interruption of the overproduction of superoxide by the mitochondrial electron transport chain would normalize the pathways involved in the development of the oxidative stress .

These findings warrant additional studies involving a larger number of patients using ultra-low microcurrent therapy. The outcomes may change the concept of management of chronic disease[69]. Conclusively, oxidative stress and oxidative damage to tissues are common pathology of chronic diseases, and using antioxidants, such as EPRT and eBalance devices may change the concept of management of chronic diseases[70].


1. Griendling KK, Fitzgerald GA. Oxidative stress and cardiovascular injury. Animal and human studies. Circulation. 2003;108:2034–2040. [PubMed[]
2. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol. 2005;25:29–38. [PubMed[]
3. Mueller CFH, Laude K, McNally JS, Harrison DG. Redox mechanisms in blood vessels. Arterioscler Thromb Vasc Biol. 2005;25:274–278. [PubMed[]
4. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem. 1997;272:20963–20966. [PubMed[]
5. Wei EP, Kontos HA, Christman CW, DeWitt DS. Superoxide generation and reversal of acetylcholine-induced cerebral arteriolar dilation after acute hypertension. Circ Res. 1985;57:781–787. [PubMed[]
6. Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol: Heart Circ Physiol. 1986;250:H822–H827. [PubMed[]
7. Maritim C, Sanders R, Watkins J. Diabetes, oxidative stress, and antioxidants: A review. J Bioch Mol Toxicol. 2003;17:24– 38. [PubMed[]
8. Baynes J, Thorpe S. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes. 1999;48:1–9. [PubMed[]
9. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–820. [PubMed[]
10. Jakus V. The role of free radicals, oxidative stress and antioxidant systems in diabetic vascular disease. Bratisl Lek Listy. 2000;101:541–51. [PubMed[]
11. Bruce CR, Carey AL, Hawley JA, Febbraio MA. Intramuscular heat shock protein 72 and heme oxygenase-1 mRNA are reduced in patients with type 2 diabetes: evidence that insulin resistance is associated with a disturbed antioxidant defense mechanism. Diabetes. 2003;52:2338–2345. [PubMed[]
12. Ceriello A, Morocutti A, Mercuri F, Quagliaro L, Moro M, Damante G, Viberti GC. Defective intracellular antioxidant enzyme production in type 1 diabetic patients with nephropathy. Diabetes. 2000;49:2170–2177. [PubMed[]
13. Hodgkinson AD, Bartlett T, Oates PJ, Millward BA, Demaine AG. The response of antioxidant genes to hyperglycemia is abnormal in patients with type 1 diabetes and diabetic nephropathy. Diabetes. 2003;52:846–851. [PubMed[]
14. Anamika M, Rasik AS. Antioxidant status in delayed healing type of wounds. Inter J Exper Path. 2000;81:257–263. [PMC free article] [PubMed[]
15. Tim J, James MS, Margaret A. Hughes, George W. Cherry, Richard P. Taylor. Evidence of oxidative stress in chronic venous ulcers. Wound Rep Reg. 1999;11:172–176. [PubMed[]
16. Paolisso G, Giugliano D. Oxidative stress and insulin action. Is there a relationship? Diabetologia. 1996;39:357–363. [PubMed[]
17. Sen CK, Khanna S, Gordillo G, Bagchi D, Bagchi M, Roy S. Oxygen, oxidants, and antioxidants in wound healing: an emerging paradigm. Ann N Y Acad Sci. 2002 May;957:239–49. [PubMed[]
18. Carley P J, Wainapel S F. Electrotherapy for acceleration of wound healing: low intensity direct current. Arch Phys Med Rehabil. 1985;66:443–446. [PubMed[]
19. Nessler JP, Mass DP. Direct-current stimulation of tendon healing in vitro. Clin Orthop. 1987;217:303–312. [PubMed[]
20. AL-Waili N. Electrotherapy for chronic gum and periapical abscesses. J Pak Med Assoc. 1989;39:161–162. [PubMed[]
21. Lee BY, Wendell K, AL-Waili N, Butler G. Ultra-low microcurrent therapy: a novel approach for treatment of chronic resistant wounds. Adv Ther. 2007;24(6):1202–9. [PubMed[]
22. Bach S, Bilgrav K, Gottrup F, Jorgensen TE. The effect of electrical current on healing skin incision: an experimental study. Eur J Surg. 1991;157:171–174. [PubMed[]
23. Carley P J, Wainapel S F. Electrotherapy for acceleration of wound healing: low intensity direct current. Arch Phys Med Rehabil. 1985;66:443–446. [PubMed[]
24. Mäenpää H, Jaakkola R, Sandström M, Von Wendt L. Does microcurrent stimulation increase the range of movement of ankle dorsiflexion in children with cerebral palsy? Disabil Rehabil. 2004;26:669–677. [PubMed[]
25. King GE, Jacob RF, Martin JW. Electrotherapy and hyperbaric oxygen: Promising treatments for postradiation complications. J Prosthetic Dentistry. 1989;62:331–334. [PubMed[]
26. Cheng N, Van Hoof H, Bockx E, Hoogmartens MJ, Mulier JC, De Dijcker FJ, Sansen WM, De Loecker W. The effects of electric currents on ATP generation, protein synthesis, and membrane transport of rat skin. Clin Orthop Relat Res. 1982;171:264–72. [PubMed[]
27. McCaig D, Rajnicek M, Song B, Zhao M. Has electrical growth cone guidance found its potential? Trends Neurosci. 2002;25:354–359. [PubMed[]
28. Zhao M, Bai H, Wang E, Forrester V, McCaig D. Electrical stimulation directly induces pre-angiogenic response in vascular endothelial cells by signaling through VEGF receptors. J Cell Sci. 2003;117:397–405. [PMC free article] [PubMed[]
29. Todd I, Clothier RH, Huggins ML, Patel N, Searle KC, Jeyarajah S, Pradel L, Lacey KL. Electrical stimulation of transforming growth factor-beta 1 secretion by human dermal fibroblasts and the U937 human monocytic cell line. Altern Lab Anim. 2001;29:693–701. [PubMed[]
30. Petersen KF, Shulman GI. New insights into the pathogenesis of insulin resistance in humans using magnetic resonance spectroscopy. Obesity (Silver Spring) 2006;14(Suppl 1):34S–40S. [PMC free article] [PubMed[]
31. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes. 1997;46:3–10. [PubMed[]
32. Evans JL, Maddux BA, Goldfine ID. The molecular basis for oxidative stress-induced insulin resistance. Antioxid Redox Signal. 2005;7:1040–1052. [PubMed[]
33. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Are oxidative stress-activated signaling pathways mediators of insulin resistance and ß-cell dysfunction? Diabetes. 2003;52:1–8. [PubMed[]
34. Robertson RP, Harmon J, Tran PO, Tanaka Y, Takahashi H. Glucose toxicity in ß-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes. 2003;52:581–587. [PubMed[]
35. Tiedge M, Lortz S, Drinkgern J, Lenzen S. Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin producing cells. Diabetes. 1997;46:1733–1742. [PubMed[]
36. El-Assad W, Buteau J, Peyot ML, Nolan C, Roduit R, Hardy S. et al.Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. Endocrinology. 2003;144:4154–4163. [PubMed[]
37. Piro S, Anello M, Di Pietro C, Lizzio MN, Patane G, Rabuazzo AM, Vigneri R, Purrello M, Purrello F. Chronic exposure to free fatty acids or high glucose induces apoptosis in rat pancreatic islets: possible role of oxidative stress. Metabolism. 2002;51:1340–1347. [PubMed[]
38. Ceriello A. The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. Diabetologia. 2003;46:M9–M16. [PubMed[]
39. Del Prato S. Loss of early insulin secretion leads to postprandial hyperglycaemia. Diabetologia. 2003;46:M2–M8. [PubMed[]
40. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature. 2000;408:239–247. [PubMed[]
41. Huang H, Manton KG. The role of oxidative damage in mitochondria during aging: a review. Front Biosci. 2004;9:1100–111. [PubMed[]
42. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404:787–790. [PubMed[]
43. Jenner P. Parkinson's disease, pesticides and mitochondrial dysfunction. Trends Neurosci. 2001;24:245–247. [PubMed[]
44. Aliev G, Seyidova D, Lamb BT, Obrenovich ME, Siedlak SL, Vinters HV, Friedland RP, LaManna JC, Smith MA, Perry G. Mitochondria and vascular lesions as a central target for the development of Alzheimer's disease and Alzheimer disease-like pathology in transgenic mice. Neurol Res. 2003;25:665–674. [PubMed[]
45. Yorek MA. The role of oxidative stress in diabetic vascular and neural disease. Free Radic Res. 2003;37:471–480. [PubMed[]
46. Schrauwen P, Hesselink MK. Oxidative capacity, lipotoxicity, and mitochondrial damage in type 2 diabetes. Diabetes. 2004;53:1412–1417. [PubMed[]
47. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–820. [PubMed[]
48. Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM, Wynshaw-Boris A, Poli G, Olefsky J, Karin M. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med. 2005;11:191–198. [PubMed[]
49. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 2005;11:183–190. [PMC free article] [PubMed[]
50. Ho E, Bray TM. Antioxidants, NFkappaB activation, and diabetogenesis. Proc Soc Exp Biol Med. 1999;222:205–213. [PubMed[]
51. Kim JK, Kim YJ, Fillmore JJ, Chen Y, Moore I, Lee J, Yuan M, Li ZW, Karin M, Perret P, Shoelson SE, Shulman GI. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest. 2001;108:437–446. [PMC free article] [PubMed[]
52. Evans L. Antioxidants: do they have a role in the management of insulin resistance. Indian J Med Res. 2007;125:355–375. [PubMed[]
53. Honjo T, Inane N. Antioxidants drugs as the strategy for treatment of metabolic syndrome. Nippon Rinsho. 2006;28:660–667. [PubMed[]
54. Davì G, Ciabottoni G, Consoli A, Messetti A, Falco A, Santarone S, Pennese E, Vitacolonna E, Bucciarelli T, Costantini F, Capani F, Patrono C. In vivo formation of 8-iso-prostaglandin F2α and platelet activation in diabetes mellitus. effects of improved metabolic control. Circulation. 1999;99:224–229. [PubMed[]
55. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840–844. [PubMed[]
56. Mehta JL, Lopez LM, Chen L, Cox OE. Alterations in nitric oxide synthase activity, superoxide anion generation, and platelet aggregation in systemic hypertension, and effects of celiprolol. Am J Cardiol. 1994;74:901–905. [PubMed[]
57. Lacy F, O'Connor DT, Schmid-Schonbein GW. Plasma hydrogen peroxide production in hypertensives and normotensive subjects at genetic risk of hypertension. J Hypertens. 1998;16:291–303. [PubMed[]
58. Zalba G, San Jose G, Moreno M, Fortuno M, Fortuno A, Beaumont F, Diez J. Oxidative stress in arterial hypertension: role of NAD(P)H oxidase. Hypertension. 2001;38:1395–1399. [PubMed[]
59. Nickenig G, Harrison DG. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. Circulation. 2002;105:393–396. [PubMed[]
60. Senel O, Cetinkale O, Ozbay G, Ahçioğlu F, Bulan R. Oxygen free radicals impair wound healing in ischemic rat skin. Ann Plast Surg. 1997;39:516–23. [PubMed[]
61. Foschi D, Trabucchi E, Musazzi M, Castoldi L, Di Mattia D, Radaelli E, Marazzi M, Franzini P, Berlusconi A. The effects of oxygen free radicals on wound healing. Int J Tissue React. 1988;10(6):373–9. [PubMed[]
62. Ceriello A. Oxidative stress and glycemic regulation. Metabolism. 2000;49:27–29. [PubMed[]
63. Tesfamariam B, Cohen RA. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Physiol. 1992;263:H321–H326. [PubMed[]
64. Marfella R, Verrazzo G, Acampora R, La Marca C, Giunta R, Lucarelli C, Paolisso G, Ceriello A, Giugliano D. Glutathione reverses systemic hemodynamic changes by acute hyperglycemia in healthy subjects. Am J Physiol. 1995;268:E1167–E1173. [PubMed[]
65. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest. 1996;97:22–28. [PMC free article] [PubMed[]
66. Marchioli R, Schweiger C, Levantesi G, Gavazzi L, Valagussa F. Antioxidant vitamins and prevention of cardiovascular disease: epidemiological and clinical trial data. Lipids. 2001;36:S53–S63. [PubMed[]
67. Cuzzocrea S, Riley DP, Caputi AP, Salvemini D. Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol Rev. 2001;53:135–159. [PubMed[]
68. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "Causal" antioxidant therapy. Diabetes Care. 2003;26:1589–1596. [PubMed[]
69. Bok Y Lee. Ultra-low microcurrent in the management of diabetes mellitus, hypertension and chronic wounds: Report of twelve cases and discussion of mechanism of action.,. 2010; 7(1): 29–35. 2009 Dec 6. 
70. An Observational Clinical Trial to Examine the Improvement of E Balance Pro Therapy on Diabetes and Related Complications. Phase IIA., 28 February 2017. CELLRPD-1600001., #255366.